资讯

Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with ...

LP-184 achieves all primary endpoints and demonstrates a favorable safety and tolerability profile positioning it for both ...

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerability Trial progressing efficiently, Cohort 4 open for ...